Recent Updates — LRMR
Larimar Therapeutics appointed John B. Harlow as President and Chief Operating Officer effective September 29, 2026. Mr. Harlow brings prior commercial leadership experience from Esperion Therapeutics, Melinta Therapeutics, and Baudax Bio. His compensation includes a $560,000 annual base salary, a $35,000 signing bonus, and a target annual bonus equal to 40% of his base salary. The company granted him an option to purchase 800,000 shares and restricted stock units for 50,000 shares as inducement grants. Severance terms provide nine months of pay and benefits upon termination without cause or for good reason, extending to twelve months following a change in control. Larimar Therapeutics operates in the biopharmaceutical industry, focusing on developing treatments for rare diseases.
Larimar Therapeutics reported a net loss of $32.8 million ($0.30 per share) for the second quarter ended June 30, 2026, compared to a $26.2 million loss in the prior year period. The company holds $156.3 million in cash and marketable securities as of June 30, projecting a runway into the third quarter of 2027. Operational highlights include the submission of the first module of a rolling Biologics License Application (BLA) seeking accelerated approval for nomlabofusp, with completion expected in the second half of 2026. Dosing of the first patient in the global confirmatory Phase 3 study is anticipated in the third quarter of 2026. The company operates as a clinical-stage biotechnology firm developing treatments for complex rare diseases.
Larimar Therapeutics, Inc. announced on June 29, 2026, that it has submitted the first module of a rolling Biologics License Application (BLA) rolling submission to the FDA for the accelerated approval of nomlabofusp. Additionally, the following long-term open-label study evaluating daily subcutaneous injections of nomlabofusp in adolescent and adult patients with Friedreich's ataxia was reported to have yielded positive data. Larimar Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for rare diseases.